Dallas, TX -- (SBWIRE) -- 09/16/2014 -- “Zontivity (Acute Coronary Syndrome) Forecast and Market Analysis to 2023?. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Under normal circumstances, thrombin proteolytically processes the platelet surface receptor protein PAR1, which initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin recognition, thereby halting platelet activation and thrombosis at this key step. Of the several receptor-mediated platelet activation pathways, the PAR1 route results in a particularly strong platelet activation response.

Complete Report Details
http://www.marketoptimizer.org/zontivity-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html

Scope:

-Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Aricept for the top seven countries from 2013 to 2023.

-Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy:

-Understand and capitalize by identifying products that are most likely to ensure a robust return

-Stay ahead of the competition by understanding the changing competitive landscape for ACS

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

-Make more informed business decisions from insightful and in-depth analysis of Aricept performance

-Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Order a Purchase copy
http://www.marketoptimizer.org/contacts/purchase?rname=10451

Table of Contents For This Report

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14

3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22

4 Disease Management 24
4.1 Treatment Overview 24

5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31

6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48

7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54

8 Alirocumab (RGN727) 59
8.1 Overview 59
8.2 Efficacy 62
8.3 Safety 64
8.4 Dosing and Formulation 64
8.5 Potential Clinical Positioning 65
8.6 Potential Commercial Positioning 65
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 67
8.9 Forecast 67

9 Appendix 69
9.1 Bibliography 69
9.2 Abbreviations 76
9.3 Methodology 80
9.4 Forecasting Methodology 80
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 80
9.4.2 Diagnosed Acute Coronary Syndrome Patients 81
9.4.3 Percent Drug-Treated Patients 82
9.4.4 General Pricing Assumptions 82
9.4.5 Generic Erosion 84
9.4.6 Pricing of Pipeline Agents 84
9.5 Physicians and Specialists Included in this Study 85
9.6 About the Authors 88
9.6.1 Author 88
9.6.2 Reviewer 88
9.6.3 Global Head of Healthcare 89
9.7 About GlobalData 90
9.8 Disclaimer 90

Browse more reports on Pharmaceuticals Market
http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals